Quantcast
Last updated on April 20, 2014 at 21:20 EDT

Latest Regulus Therapeutics Stories

2013-04-30 08:35:05

JUPITER, Fla., April 30, 2013 /PRNewswire/ -- SMaRT Therapeutics, Inc., a leading biotechnology company focused on the development of small-molecule drugs that target and modulate RNA, announced the appointment of Dr. John H. Abeles to its Advisory Board. Dr. Abeles has had a long and distinguished career in the biotechnology and pharmaceutical industries. He practiced medicine in London before serving as a Senior Medical Executive with Sterling Drug, Pfizer and Revlon Healthcare. He...

2013-04-24 16:25:53

LA JOLLA, Calif., April 24, 2013 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that Kleanthis G. Xanthopoulos, Ph.D., President and Chief Executive Officer, will present a company overview at the 12(th) Annual Needham Healthcare Conference on Wednesday, May 1, 2013 at 12:10 pm EDT. The conference is being held at the Westin Grand Central Hotel in New...

2013-04-22 16:26:15

CARLSBAD, Calif., April 22, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the 12(th) Annual Needham Healthcare Conference on Tuesday, April 30, 2013 at 11:20 a.m. ET in New York, NY. A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's Web site, www.isispharm.com. A replay will be available on the Isis Web...

2013-03-28 16:24:47

LA JOLLA, Calif., March 28, 2013 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that Garry E. Menzel, Ph.D., Chief Operating Officer and Executive Vice President, Finance, will present a company overview at the 20(th) Annual Future Leaders in the Biotech Industry Conference on Friday, April 5, 2013 at 10:30 am EDT. The conference is being held at the...

2013-03-15 08:26:19

CARLSBAD, Calif., March 15, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the 25(th) Annual ROTH Conference on Tuesday, March 19, 2013 at 8:00 a.m. PT in Laguna Niguel, CA. A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's Web site, www.isispharm.com. A replay will be available on the Isis Web site within...

2013-03-06 08:26:04

CARLSBAD, Calif., March 6, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the Barclays Global Healthcare Conference on Wednesday, March 13, 2013 at 2:00 p.m. ET in Miami, FL. A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's Web site, www.isispharm.com. A replay will be available on the Isis Web site within...

2013-02-28 08:30:19

- Conference Call Webcast Thursday, February 28, 12:00 p.m. ET at www.isispharm.com CARLSBAD, Calif., Feb. 28, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today announced its 2012 financial results and reviewed the highlights of the year. Isis ended the year in a strong financial position significantly outperforming both its pro forma net operating loss (NOL) guidance and its cash guidance for the year. For the year ended December 31, 2012, Isis had an NOL of...

2013-02-27 08:28:14

CARLSBAD, Calif., Feb. 27, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the Cowen and Company 33(rd) Annual Health Care Conference on Wednesday, March 6, 2013 at 8:40 a.m. ET in Boston, MA. A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's Web site, www.isispharm.com. A replay will be available on...

2013-02-26 16:27:26

LA JOLLA, Calif., Feb. 26, 2013 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that Garry E. Menzel, Ph.D., Chief Operating Officer and Executive Vice President, Finance, will present a company overview at the Cowen and Company 33rd Annual Healthcare Conference on Tuesday, March 5, 2013 at 8:40 am EST. The conference is being held at the Boston Marriott...

2013-02-26 08:28:54

CARLSBAD, Calif., Feb. 26, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced the initiation of a Phase 2 study evaluating ISIS-CRP(Rx) in patients with paroxysmal atrial fibrillation. Atrial fibrillation (AF) involves an irregular and often rapid heart rate that commonly causes poor blood flow to the body. Paroxysmal AF is a type of AF characterized by unpredictable episodes of AF that can occur as frequently as every day. Patients with AF can experience chest...